Immunotherapy to treat malignancy in patients with pre-existing autoimmunity by Jeffrey Weber, Patrick Boland, Anna C Pavlick, Sabina Sandigursky

Get full text

Response to: Association of selected (immune-related) adverse events and outcome in two adjuvant phase III trials, Checkmate-238 and EORTC1325/KEYNOTE-054 by Eggermont et al by James Larkin, Jeffrey Weber, Paolo Antonio Ascierto, Mario Mandala

Get full text

Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition by Jeffrey Weber, David Woods, Andressa S Laino, Melinda Vassallo, Xiaozhong Qian, Hao Tang, Megan Wind-Rotolo

Get full text

A genome-wide association study of germline variation and melanoma prognosis by Vylyny Chat, Vylyny Chat, Vylyny Chat, Sasha Dagayev, Sasha Dagayev, Sasha Dagayev, Una Moran, Una Moran, Matija Snuderl, Jeffrey Weber, Jeffrey Weber, Robert Ferguson, Robert Ferguson, Robert Ferguson, Iman Osman, Iman Osman, Iman Osman, Tomas Kirchhoff, Tomas Kirchhoff, Tomas Kirchhoff

Get full text

C reactive protein impairs adaptive immunity in immune cells of patients with melanoma by Jeffrey Weber, Michelle Krogsgaard, Tatsuya Yoshida, Junya Ichikawa, Iulia Giuroiu, Andressa S Laino, Yuhan Hao, Melinda Vassallo, David M Woods, F Stephen Hodi

Get full text

Tumor immunogenomic signatures improve a prognostic model of melanoma survival by Leah Morales, Danny Simpson, Robert Ferguson, John Cadley, Eduardo Esteva, Kelsey Monson, Vylyny Chat, Carlos Martinez, Jeffrey Weber, Iman Osman, Tomas Kirchhoff

Get full text

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology by Laura C Cappelli, Maria E Suarez-Almazor, Michelle Turner, Stephane Champiat, Caroline Robert, Julie R Brahmer, Jarushka Naidoo, Jeffrey Weber, Joanne Riemer, Elad Sharon, Michael B Atkins, M Catherine Pietanza, Karthik Suresh, Catherine Murphy, Javid Moslehi, David Feltquate, Lee M Krug

Get full text

776 Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144–01 study by James Larkin, Harriet Kluger, Omid Hamid, Jeffrey Weber, Amod A Sarnaik, Brian Gastman, Jeffrey Chou, John M Kirkwood, Eric Whitman, Martin Wermke, Evidio Domingo-Musibay, Theresa Medina, Sajeve Thomas, Wen Shi, Xiao Wu, Jason A Chesney, Giri Sulur, Friedrich Graf Finckenstein

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma by Judith D Goldberg, Joseph Markowitz, Jeffrey Weber, Ragini Kudchadkar, Tomas Kirchhoff, Anna Pavlick, Zeynep Eroglu, Melinda Vassallo, David M Woods, Andrew S Brohl, Nikhil I Khushalani, Alison Richards, Younchul Kim, Biwei Cao, Robert Ferguson, Kelsey R Monson, Carol M Amato, Paulo Burke, Ann Strange, Emily Monk, Geoffrey Thomas Gibney

Get full text

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint... by Jessica C Hassel, James Larkin, Madan Jagasia, Harriet Kluger, Omid Hamid, Jeffrey Weber, Jason Chesney, Amod Sarnaik, John M Kirkwood, Eric Whitman, Martin Wermke, Evidio Domingo-Musibay, Theresa Medina, Sajeve Thomas, Wen Shi, Xiao Wu, Nikhil I Khushalani, Parameswaran Hari, Marlana Orloff, Mike Cusnir, Giao Q Phan, Andrew J S Furness, Michael E Egger, Friedrich Graf Finckenstein, Giri Sulur

Get full text

1530 T-cell responses to individualized neoantigen therapy (INT) mRNA-4157 (V940) as monotherapy or in combination with pembrolizumab by Wei Zheng, Jing Sun, Jeffrey Weber, Manish R Patel, Brandon Coder, Igor Feldman, Justin F Gainor, Jessica L Geiger, Martin Gutierrez, Joshua Frederick, Celine Robert-Tissot, Robert Meehan, Jack Pollard, Lakshmi Srinivasan, Michelle Brown, Kedar Kirtane, Julie E Bauman, Praveen Aanur, Jeffrey M Clarke, Ricklie A Julian, Aaron J Scott, Moomal Tasneem, Lauren Gerbereux, Andressa Laino, Peijie Hou, Vasudha Sehgal, Hikmat N Daghestani, Howard A Burris

579-C Reinvigoration of progenitor-exhausted CD8 T cells by anti-CTLA-4 contributes to the sustained activity of combination checkpoint blockade by Xiaowei Xu, Wei Xu, Alexander Huang, Jeffrey Weber, Andy Minn, Kevin Wang, Tara Mitchell, Sasikanth Manne, Divij Mathew, E John Wherry, Daniel Tenney, Paulina Coutifaris, David Brocks, Sabrina Solis, Nicholas Han, Evgeny Kiner, Chirag Sachar, Sangeeth George, Patrick Yan, Melanie W Kiner, Amy I Laughlin, Shawn Kothari, Josephine R Giles, Rheem Ghinnagow, Cecile Alanio, Ahron Flowers, Ravi K Amaravadi, Giorgos C Karakousis, Lynn M Schuchter, Marcus Buggert, Ramin S Herati

Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events by Namrata Singh, Maria E Suarez-Almazor, Iman Osman, Jeffrey Weber, Adi Diab, Petros Grivas, Noha Abdel-Wahab, Ala Abudayyeh, Huifang Lu, Osama Rahma, Daniel H Johnson, Chrystia M Zobniw, Van A Trinh, Juhee Song, Jeffrey A Sparks, Sabina Sandigursky, Maya Dimitrova, May Daher, Maryam Buni, Kaysia Ludford, Faisal Fa'ak, Sarah H Chung, Uma Thanarajasingam, Adewunmi Falohun, Muhammad Osama Awiwi, Nourel Hoda Tahon, Khaled M Elsayes, Emma J Montazari, Julia Chernis, Osama Abu-Shawer, Ashley M Zeman, Rafee Talukder, Jean H Tayar

Get full text